TECLISON

We have forged collaborations with top-tier companies, partnering with Merck to develop our treatment platform. We are committed to pioneering new ways to effectively treat patients with solid tumor cancers who respond poorly to existing immunotherapies... Our innovative approaches aim to enhance immune checkpoint inhibitors (ICIs) and prolong the lives of patients with solid tumor cancers that have metastasized to the liver... At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.

Also known as: Teclison Limited, Teclison, Inc.

Primary location: Princeton United States